Gustaf J. Wellhagen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gustaf J. Wellhagen has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Maria C. Kjellsson
Pharmacometrics Research Group, Department of Pharmacy Uppsala University Uppsala Sweden
5 shared publications - Mats O. Karlsson
Department of Pharmacy, Uppsala University , Uppsala
4 shared publications Ashraf Yassen
Bayer AG Wuppertal Germany
2 shared publicationsAstrid Bröker
Bayer AG Wuppertal Germany
2 shared publicationsDirk Garmann
Bayer AG Wuppertal Germany
2 shared publicationsMaria C. Kjellsson
Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden
2 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (11) , e70349
Longitudinal Modeling of Cardiometabolic Dysfunction in Patients With Type 2 Diabetes Using Item Response Theory
Cardiometabolic dysfunction in patients with type 2 diabetes (T2D) is reflected by multiple risk factors and cannot be fully characterized by any single biomarker. Item response theory (IRT) provides a framework for integrating observed risk factors into latent measures of underlying cardiometabolic dysfunction. Routinely collected measurements of systolic and diastolic blood pressure (sBP and dBP), high‐ and low‐density lipoproteins (HDL and LDL), triglycerides (TG), HbA1c, and BMI from 33,396 adults newly diagnosed with T2D were analyzed, with biomarkers categorized into four ordered levels. A two‐dimensional model described the data better than a unidimensional, identifying a blood pressure‐related latent variable ( 1 ) primarily informed by sBP and dBP, and a metabolic latent variable ( 2 ) primarily informed by HDL, HbA1c, TG, and BMI, while LDL showed low discrimination on both dimensions. At baseline, age at T2D diagnosis was associated with both latent variables, with opposing effects of 0.02 for 1 and −0.07 for 2 . Sex was associated with 2 , with women scoring 0.43 units lower than men on the latent variable scale. Longitudinally, 1 and 2 showed post‐baseline offsets of −0.10 and −0.22, respectively, followed by separately estimated annual slopes of approximately −0.03 year −1 . HbA1c exhibited a distinct trajectory with an initial post‐baseline improvement followed by deterioration, requiring an item‐specific slope of 0.45 year −1 . The 2 contributed modest additional information for all‐cause mortality beyond age and sex. This framework integrated routinely collected biomarkers into continuous latent measures of multidimensional cardiometabolic dysfunction while accounting for differences in their contributions to the latent dimensions.
- 15 October 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (11) , e70349
Open AccessLongitudinal Modeling of Cardiometabolic Dysfunction in Patients With Type 2 Diabetes Using Item Response Theory
Cardiometabolic dysfunction in patients with type 2 diabetes (T2D) is reflected by multiple risk factors and cannot be fully characterized by any single biomarker. Item response theory (IRT) provides a framework for integrating observed risk factors into latent measures of underlying cardiometabolic dysfunction. Routinely collected measurements of systolic and diastolic blood pressure (sBP and dBP), high‐ and low‐density lipoproteins (HDL and LDL), triglycerides (TG), HbA1c, and BMI from 33,396 adults newly diagnosed with T2D were analyzed, with biomarkers categorized into four ordered levels. A two‐dimensional model described the data better than a unidimensional, identifying a blood pressure‐related latent variable ( 1 ) primarily informed by sBP and dBP, and a metabolic latent variable ( 2 ) primarily informed by HDL, HbA1c, TG, and BMI, while LDL showed low discrimination on both dimensions. At baseline, age at T2D diagnosis was associated with both latent variables, with opposing effects of 0.02 for 1 and −0.07 for 2 . Sex was associated with 2 , with women scoring 0.43 units lower than men on the latent variable scale. Longitudinally, 1 and 2 showed post‐baseline offsets of −0.10 and −0.22, respectively, followed by separately estimated annual slopes of approximately −0.03 year −1 . HbA1c exhibited a distinct trajectory with an initial post‐baseline improvement followed by deterioration, requiring an item‐specific slope of 0.45 year −1 . The 2 contributed modest additional information for all‐cause mortality beyond age and sex. This framework integrated routinely collected biomarkers into continuous latent measures of multidimensional cardiometabolic dysfunction while accounting for differences in their contributions to the latent dimensions.
- Open Access
- 4 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2244-2251
Predictors of Ability to Work in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic disorder that typically shows accumulation of disability, affecting the ability to work. The disease severity is usually graded by physicians with the expanded disability status scale (EDSS) in the clinic, but patient‐reported outcome questionnaires are also available, like the Multiple Sclerosis Impact Scale (MSIS‐29) or Fatigue Scale for Motor and Cognitive Functions (FSMC). The aim of this work was to investigate the quantitative link between disease severity and the number of days with MS‐related sickness benefits from registry data (the Swedish MS registry and the Swedish Social Insurance Agency's Micro Data for Analyzes of Social Insurance registry). An item response theory model for the disability was built, linking the EDSS, MSIS‐29, and FSMC to the same underlying disease construct through five correlated latent variables. A Markov state model for the level of sickness benefits was also developed, in which the disease severities from the disability model were tested as covariates, on top of age. The latent variable for EDSS was the most important predictor of work ability. Patients with low disability (EDSS < 3) hardly had any sickness benefit days, while patients with severe disability (EDSS ≥ 6) were found to spend over 50% of their time with sickness benefits. Physical aspects of the disease were found to be more important than psychological aspects in predicting work ability. This underlines the patient‐specific nature of MS, and the need for predictive models such as these to evaluate treatment effects, make risk assessments, and calculate societal and individual costs.
- 4 November 2025
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 14 (12) , 2244-2251
Open AccessPredictors of Ability to Work in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic disorder that typically shows accumulation of disability, affecting the ability to work. The disease severity is usually graded by physicians with the expanded disability status scale (EDSS) in the clinic, but patient‐reported outcome questionnaires are also available, like the Multiple Sclerosis Impact Scale (MSIS‐29) or Fatigue Scale for Motor and Cognitive Functions (FSMC). The aim of this work was to investigate the quantitative link between disease severity and the number of days with MS‐related sickness benefits from registry data (the Swedish MS registry and the Swedish Social Insurance Agency's Micro Data for Analyzes of Social Insurance registry). An item response theory model for the disability was built, linking the EDSS, MSIS‐29, and FSMC to the same underlying disease construct through five correlated latent variables. A Markov state model for the level of sickness benefits was also developed, in which the disease severities from the disability model were tested as covariates, on top of age. The latent variable for EDSS was the most important predictor of work ability. Patients with low disability (EDSS < 3) hardly had any sickness benefit days, while patients with severe disability (EDSS ≥ 6) were found to spend over 50% of their time with sickness benefits. Physical aspects of the disease were found to be more important than psychological aspects in predicting work ability. This underlines the patient‐specific nature of MS, and the need for predictive models such as these to evaluate treatment effects, make risk assessments, and calculate societal and individual costs.
- Open Access
- 12 March 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (5) , 880-890
Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
Obstructive sleep apnea (OSA) is a sleep disorder which is linked to many health risks. The gold standard to evaluate OSA in clinical trials is the Apnea‐Hypopnea Index (AHI). However, it is time‐consuming, costly, and disregards aspects such as quality of life. Therefore, it is of interest to use patient‐reported outcomes like the Epworth Sleepiness Scale (ESS), which measures daytime sleepiness, as surrogate end points. We investigate the link between AHI and ESS, via item response theory (IRT) modeling. Through the developed IRT model it was identified that AHI and ESS are not correlated to any high degree and probably not measuring the same sleepiness construct. No covariate relationships of clinical relevance were found. This suggests that ESS is a poor choice as an end point for clinical development if treatment is targeted at improving AHI, and especially so in a mild OSA patient group.
- 12 March 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (5) , 880-890
Open AccessItem response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
Obstructive sleep apnea (OSA) is a sleep disorder which is linked to many health risks. The gold standard to evaluate OSA in clinical trials is the Apnea‐Hypopnea Index (AHI). However, it is time‐consuming, costly, and disregards aspects such as quality of life. Therefore, it is of interest to use patient‐reported outcomes like the Epworth Sleepiness Scale (ESS), which measures daytime sleepiness, as surrogate end points. We investigate the link between AHI and ESS, via item response theory (IRT) modeling. Through the developed IRT model it was identified that AHI and ESS are not correlated to any high degree and probably not measuring the same sleepiness construct. No covariate relationships of clinical relevance were found. This suggests that ESS is a poor choice as an end point for clinical development if treatment is targeted at improving AHI, and especially so in a mild OSA patient group.
- Open Access
- 4 March 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (5) , 812-822
Evaluation of covariate effects in item response theory models
Item response theory (IRT) models are usually the best way to analyze composite or rating scale data. Standard methods to evaluate covariate or treatment effects in IRT models do not allow to identify item‐specific effects. Finding subgroups of patients who respond differently to certain items could be very important when designing inclusion or exclusion criteria for clinical trials, and aid in understanding different treatment responses in varying disease manifestations. We present a new method to investigate item‐specific effects in IRT models, which is based on inspection of residuals. The method was investigated in a simulation exercise with a model for the Epworth Sleepiness Scale. We also provide a detailed discussion as a guidance on how to build a robust covariate IRT model.
- 4 March 2024
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 13 (5) , 812-822
Open AccessEvaluation of covariate effects in item response theory models
Item response theory (IRT) models are usually the best way to analyze composite or rating scale data. Standard methods to evaluate covariate or treatment effects in IRT models do not allow to identify item‐specific effects. Finding subgroups of patients who respond differently to certain items could be very important when designing inclusion or exclusion criteria for clinical trials, and aid in understanding different treatment responses in varying disease manifestations. We present a new method to investigate item‐specific effects in IRT models, which is based on inspection of residuals. The method was investigated in a simulation exercise with a model for the Epworth Sleepiness Scale. We also provide a detailed discussion as a guidance on how to build a robust covariate IRT model.
- Open Access
- 27 December 2021
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (4) , 1014-1026
Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal dosing regimen for Japanese patients with T2DM and chronic kidney disease (CKD). Imeglimin plasma concentrations in Japanese and Western healthy volunteers, and patients with T2DM, including patients with mild to severe CKD with an estimated glomerular filtration rate (eGFR) greater than 14 ml/min/1.73 m2were included in a population PK analysis. PK simulations were conducted using a population PK model, and the area under concentration‐time curve (AUC) was extrapolated with power regression analysis to lower eGFR. The influence of eGFR, weight, and age on apparent clearance and of dose on relative bioavailability were quantified by population PK analysis. Simulations and extrapolation revealed that the recommended dosing regimen based on the AUC was 500 mg twice daily (b.i.d.) for patients with eGFR 15–45 ml/min/1.73 m2, and 500 mg with a longer dosing interval was suggested for those with eGFR less than 15. Simulations revealed that differences in plasma AUCs between Japanese and Western patients at the same dose were mainly driven by a difference in the eGFR and that the plasma AUC after 1000 and 1500 mg b.i.d. in Japanese and Western patients, respectively, was comparable in the phase IIb studies. These results indicate suitable dosages of imeglimin in the clinical setting of T2DM with renal impairment.
- 27 December 2021
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (4) , 1014-1026
Open AccessImeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal dosing regimen for Japanese patients with T2DM and chronic kidney disease (CKD). Imeglimin plasma concentrations in Japanese and Western healthy volunteers, and patients with T2DM, including patients with mild to severe CKD with an estimated glomerular filtration rate (eGFR) greater than 14 ml/min/1.73 m2were included in a population PK analysis. PK simulations were conducted using a population PK model, and the area under concentration‐time curve (AUC) was extrapolated with power regression analysis to lower eGFR. The influence of eGFR, weight, and age on apparent clearance and of dose on relative bioavailability were quantified by population PK analysis. Simulations and extrapolation revealed that the recommended dosing regimen based on the AUC was 500 mg twice daily (b.i.d.) for patients with eGFR 15–45 ml/min/1.73 m2, and 500 mg with a longer dosing interval was suggested for those with eGFR less than 15. Simulations revealed that differences in plasma AUCs between Japanese and Western patients at the same dose were mainly driven by a difference in the eGFR and that the plasma AUC after 1000 and 1500 mg b.i.d. in Japanese and Western patients, respectively, was comparable in the phase IIb studies. These results indicate suitable dosages of imeglimin in the clinical setting of T2DM with renal impairment.
- Open Access
- 31 July 2020
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (8) , 1-9
Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response
Purpose: In this paper we investigated a new method for dose-response analysis of longitudinal data in terms of precision and accuracy using simulations.Methods: The new method, called Dose-Response Mixed Models for Repeated Measures (DR-MMRM), combines conventional Mixed Models for Repeated Measures (MMRM) and dose-response modeling. Conventional MMRM can be applied for highly variable repeated measure data and is a way to estimate the drug effect at each visit and dose, however without any assumptions regarding the dose-response shape. Dose-response modeling, on the other hand, utilizes information across dose arms and describes the drug effect as a function of dose. Drug development in chronic kidney disease (CKD) is complicated by many factors, primarily by the slow progression of the disease and lack of predictive biomarkers. Recently, new approaches and biomarkers are being explored to improve efficiency in CKD drug development. Proteinuria, i.e. urinary albumin-to-creatinine ratio (UACR) is increasingly used in dose finding trials in patients with CKD. We use proteinuria to illustrate the benefits of DR-MMRM.Results: The DR-MMRM had higher precision than conventional MMRM and less bias than a dose-response model on UACR change from baseline to end-of-study (DR-EOS).Conclusions: DR-MMRM is a promising method for dose-response analysis.
- 31 July 2020
- Published by Springer Nature in Pharmaceutical Research
- Vol. 37 (8) , 1-9
Open AccessDose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response
Purpose: In this paper we investigated a new method for dose-response analysis of longitudinal data in terms of precision and accuracy using simulations.Methods: The new method, called Dose-Response Mixed Models for Repeated Measures (DR-MMRM), combines conventional Mixed Models for Repeated Measures (MMRM) and dose-response modeling. Conventional MMRM can be applied for highly variable repeated measure data and is a way to estimate the drug effect at each visit and dose, however without any assumptions regarding the dose-response shape. Dose-response modeling, on the other hand, utilizes information across dose arms and describes the drug effect as a function of dose. Drug development in chronic kidney disease (CKD) is complicated by many factors, primarily by the slow progression of the disease and lack of predictive biomarkers. Recently, new approaches and biomarkers are being explored to improve efficiency in CKD drug development. Proteinuria, i.e. urinary albumin-to-creatinine ratio (UACR) is increasingly used in dose finding trials in patients with CKD. We use proteinuria to illustrate the benefits of DR-MMRM.Results: The DR-MMRM had higher precision than conventional MMRM and less bias than a dose-response model on UACR change from baseline to end-of-study (DR-EOS).Conclusions: DR-MMRM is a promising method for dose-response analysis.
- Open Access
- 6 June 2019
- Published by Springer Nature in The AAPS Journal
- Vol. 21 (4) , 1-8
A Bounded Integer Model for Rating and Composite Scale Data
Rating and composite scales are commonly used to assess treatment efficacy. The two main strategies for modelling such endpoints are to treat them as a con
- 6 June 2019
- Published by Springer Nature in The AAPS Journal
- Vol. 21 (4) , 1-8
Open AccessA Bounded Integer Model for Rating and Composite Scale Data
Rating and composite scales are commonly used to assess treatment efficacy. The two main strategies for modelling such endpoints are to treat them as a con
- 29 September 2018
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 124 (1) , 105-114
Using a semi‐mechanistic model to identify the main sources of variability of metformin pharmacokinetics
Metformin pharmacokinetics (PK) is highly variable, and researchers have for years tried to shed light on determinants of inter‐individual (IIV) and inter‐occasion variability (IOV) of metformin PK. We set out to identify the main sources of PK variability using a semi‐mechanistic model. We assessed the influence of subject characteristics, including seven genetic variants. Data from three studies of healthy individuals with PK measurements of plasma and urine after single dose or at steady‐state were used in this study. In total, 87 subjects were included (16 crossover subjects). Single nucleotide polymorphisms in ATM, OCT1, OCT2, MATE1 and MATE2‐K were investigated as dominant, recessive or additive. A three‐compartment model with transit absorption and renal elimination with a proportional error was fitted to the data using NONMEM 7.3. Oral parameters were separated from disposition parameters as dose‐dependent absolute bioavailability was determined with support from urine data. Clearance was expressed as net renal secretion and filtration, assuming full fraction unbound and fraction excreted. Mean transit time and peripheral volume of distribution were identified as the main sources of variability according to estimates, with 94% IOV and 95% IIV, respectively. Clearance contributed only with 16% IIV. Glomerular filtration rate and body‐weight were the only covariates found to affect metformin net secretion, reducing IIV to 14%. None of the genetic variants were found to affect metformin PK. Based on our analysis, finding covariates explaining absorption of metformin is much more valuable in understanding variability and avoiding toxicity than elimination.
- 29 September 2018
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 124 (1) , 105-114
Using a semi‐mechanistic model to identify the main sources of variability of metformin pharmacokinetics
Metformin pharmacokinetics (PK) is highly variable, and researchers have for years tried to shed light on determinants of inter‐individual (IIV) and inter‐occasion variability (IOV) of metformin PK. We set out to identify the main sources of PK variability using a semi‐mechanistic model. We assessed the influence of subject characteristics, including seven genetic variants. Data from three studies of healthy individuals with PK measurements of plasma and urine after single dose or at steady‐state were used in this study. In total, 87 subjects were included (16 crossover subjects). Single nucleotide polymorphisms in ATM, OCT1, OCT2, MATE1 and MATE2‐K were investigated as dominant, recessive or additive. A three‐compartment model with transit absorption and renal elimination with a proportional error was fitted to the data using NONMEM 7.3. Oral parameters were separated from disposition parameters as dose‐dependent absolute bioavailability was determined with support from urine data. Clearance was expressed as net renal secretion and filtration, assuming full fraction unbound and fraction excreted. Mean transit time and peripheral volume of distribution were identified as the main sources of variability according to estimates, with 94% IOV and 95% IIV, respectively. Clearance contributed only with 16% IIV. Glomerular filtration rate and body‐weight were the only covariates found to affect metformin net secretion, reducing IIV to 14%. None of the genetic variants were found to affect metformin PK. Based on our analysis, finding covariates explaining absorption of metformin is much more valuable in understanding variability and avoiding toxicity than elimination.
- Open Access
- 25 March 2018
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 7 (5) , 331-341
Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes
Reusing published models saves time; time to be used for informing decisions in drug development. In antihyperglycemic drug development, several published HbA1c models are available but selecting the appropriate model for a particular purpose is challenging. This study aims at helping selection by investigating four HbA1c models, specifically the ability to identify drug effects (shape, site of action, and power) and simulation properties. All models could identify glucose effect nonlinearities, although for detecting the site of action, a mechanistic glucose model was needed. Power was highest for models using mean plasma glucose to drive HbA1c formation. Insulin contribution to power varied greatly depending on the drug target; it was beneficial only if the drug target was insulin secretion. All investigated models showed good simulation properties. However, extrapolation with the mechanistic model beyond 12 weeks resulted in drug effect overprediction. This investigation aids drug development in decisions regarding model choice if reusing published HbA1c models.
- 25 March 2018
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 7 (5) , 331-341
Open AccessComparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes
Reusing published models saves time; time to be used for informing decisions in drug development. In antihyperglycemic drug development, several published HbA1c models are available but selecting the appropriate model for a particular purpose is challenging. This study aims at helping selection by investigating four HbA1c models, specifically the ability to identify drug effects (shape, site of action, and power) and simulation properties. All models could identify glucose effect nonlinearities, although for detecting the site of action, a mechanistic glucose model was needed. Power was highest for models using mean plasma glucose to drive HbA1c formation. Insulin contribution to power varied greatly depending on the drug target; it was beneficial only if the drug target was insulin secretion. All investigated models showed good simulation properties. However, extrapolation with the mechanistic model beyond 12 weeks resulted in drug effect overprediction. This investigation aids drug development in decisions regarding model choice if reusing published HbA1c models.
- Top Cited Papers
- 24 August 2014
- Published by Springer Nature in Nature Genetics
- Vol. 46 (10) , 1081-1088
A worldwide survey of genome sequence variation provides insight into the evolutionary history of the honeybee Apis mellifera
The honeybee Apis mellifera has major ecological and economic importance. We analyze patterns of genetic variation at 8.3 million SNPs, identified by sequencing 140 honeybee genomes from a worldwide sample of 14 populations at a combined total depth of 634×. These data provide insight into the evolutionary history and genetic basis of local adaptation in this species. We find evidence that population sizes have fluctuated greatly, mirroring historical fluctuations in climate, although contemporary populations have high genetic diversity, indicating the absence of domestication bottlenecks. Levels of genetic variation are strongly shaped by natural selection and are highly correlated with patterns of gene expression and DNA methylation. We identify genomic signatures of local adaptation, which are enriched in genes expressed in workers and in immune system– and sperm motility–related genes that might underlie geographic variation in reproduction, dispersal and disease resistance. This study provides a framework for future investigations into responses to pathogens and climate change in honeybees.
- 24 August 2014
- Published by Springer Nature in Nature Genetics
- Vol. 46 (10) , 1081-1088
Top Cited PapersA worldwide survey of genome sequence variation provides insight into the evolutionary history of the honeybee Apis mellifera
The honeybee Apis mellifera has major ecological and economic importance. We analyze patterns of genetic variation at 8.3 million SNPs, identified by sequencing 140 honeybee genomes from a worldwide sample of 14 populations at a combined total depth of 634×. These data provide insight into the evolutionary history and genetic basis of local adaptation in this species. We find evidence that population sizes have fluctuated greatly, mirroring historical fluctuations in climate, although contemporary populations have high genetic diversity, indicating the absence of domestication bottlenecks. Levels of genetic variation are strongly shaped by natural selection and are highly correlated with patterns of gene expression and DNA methylation. We identify genomic signatures of local adaptation, which are enriched in genes expressed in workers and in immune system– and sperm motility–related genes that might underlie geographic variation in reproduction, dispersal and disease resistance. This study provides a framework for future investigations into responses to pathogens and climate change in honeybees.